High Levels of SII and PIV are the Risk Factors of Axillary Lymph Node Metastases in Breast Cancer: A Retrospective Study

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Barrio AV, Montagna G, Mamtani A, et al. Nodal recurrence in patients with node-positive breast cancer treated with sentinel node biopsy alone after neoadjuvant chemotherapy-a rare event. JAMA Oncol. 2021;7(12):1851–1855. doi:10.1001/jamaoncol.2021.4394
   PubMed Web of Science ®Google Scholar
• Pilger TL, Francisco DF, Candido Dos Reis FJ. Effect of sentinel lymph node biopsy on upper limb function in women with early breast cancer: a systematic review of clinical trials. Eur J Surg Oncol. 2021;47(7):1497–1506. doi:10.1016/j.ejso.2021.01.024
   PubMed Web of Science ®Google Scholar
• Cortina CS, Yen T, Bergom C, et al. Breast cancer-related lymphedema rates after modern axillary treatments: how accurate are our estimates. Surgery. 2022;171(3):682–686. doi:10.1016/j.surg.2021.08.019
   PubMed Web of Science ®Google Scholar
• Alameen S, Tamam N, Awadain S, Sulieman A, Alkhaldi L, Hmed AB. Radiobiological risks in terms of effective dose and organ dose from (18) F-FDGwhole-body PET/CT procedures. Saudi J Biol Sci. 2021;28(10):5947–5951. doi:10.1016/j.sjbs.2021.06.055
   PubMed Web of Science ®Google Scholar
• Davidson T, Shehade N, Nissan E, et al. PET/CT in breast cancer staging is useful for evaluation of axillary lymph node and distant metastases. Surg Oncol. 2021;38:101567. doi:10.1016/j.suronc.2021.101567
   PubMed Web of Science ®Google Scholar
• Khandia R, Munjal A. Interplay between inflammation and cancer. Adv Protein Chem Struct Biol. 2020;119:199–245.
   PubMed Web of Science ®Google Scholar
• Huang H, Liu Q, Zhu L, et al. Prognostic value of preoperative systemic immune-inflammation index in patients with cervical cancer. Sci Rep. 2019;9(1):3284. doi:10.1038/s41598-019-39150-0
   PubMed Web of Science ®Google Scholar
• Matsubara S, Mabuchi S, Takeda Y, Kawahara N, Kobayashi H. Prognostic value of pre-treatment systemic immune-inflammation index in patients with endometrial cancer. PLoS One. 2021;16(5):e0248871. doi:10.1371/journal.pone.0248871
   PubMed Web of Science ®Google Scholar
• Chen JH, Zhai ET, Yuan YJ, et al. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J Gastroenterol. 2017;23(34):6261–6272. doi:10.3748/wjg.v23.i34.6261
   PubMed Web of Science ®Google Scholar
• Fucà G, Guarini V, Antoniotti C, et al. The pan-immune-inflammation value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. Br J Cancer. 2020;123(3):403–409. doi:10.1038/s41416-020-0894-7
   PubMed Web of Science ®Google Scholar
• Hua X, Long ZQ, Zhang YL, et al. Prognostic value of preoperative systemic immune-inflammation index in breast cancer: a propensity score-matching study. Front Oncol. 2020;10:580. doi:10.3389/fonc.2020.00580
   PubMed Web of Science ®Google Scholar
• Şahin AB, Cubukcu E, Ocak B, et al. Low pan-immune-inflammation-value predicts better chemotherapy response and survival in breast cancer patients treated with neoadjuvant chemotherapy. Sci Rep. 2021;11(1):14662. doi:10.1038/s41598-021-94184-7
   PubMed Web of Science ®Google Scholar
• Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784–2795. doi:10.1200/JCO.2009.25.6529
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond ME, Allison KH, Harvey BE, McShane LM and Dowsett M. (2018). HER2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Summary. JOP, 14(7), 437–441. 10.1200/JOP.18.00206
   PubMedGoogle Scholar
• Muftah AA, Aleskandarany MA, Al-Kaabi MM, et al. Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections. Breast Cancer Res Treat. 2017;164(2):341–348. doi:10.1007/s10549-017-4270-0
   PubMed Web of Science ®Google Scholar
• Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27–41. doi:10.1016/j.immuni.2019.06.025
   PubMed Web of Science ®Google Scholar
• Kay J, Thadhani E, Samson L, Engelward B. Inflammation-induced DNA damage, mutations and cancer. DNA Repair (Amst). 2019;83:102673. doi:10.1016/j.dnarep.2019.102673
   PubMed Web of Science ®Google Scholar
• Duits D, de Visser KE. Impact of cancer cell-intrinsic features on neutrophil behavior. Semin Immunol. 2021;57:101546. doi:10.1016/j.smim.2021.101546
   PubMed Web of Science ®Google Scholar
• Ugel S, Canè S, De Sanctis F, Bronte V. Monocytes in the tumor microenvironment. Annu Rev Pathol. 2021;16:93–122. doi:10.1146/annurev-pathmechdis-012418-013058
   PubMed Web of Science ®Google Scholar
• Schlesinger M. Role of platelets and platelet receptors in cancer metastasis. J Hematol Oncol. 2018;11(1):125. doi:10.1186/s13045-018-0669-2
   PubMed Web of Science ®Google Scholar
• Stanton SE, Disis ML. Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer. 2016;4:59. doi:10.1186/s40425-016-0165-6
   PubMed Web of Science ®Google Scholar
• Zhang Y, Sun Y, Zhang Q. Prognostic value of the systemic immune-inflammation index in patients with breast cancer: a meta-analysis. Cancer Cell Int. 2020;20:224. doi:10.1186/s12935-020-01308-6
   PubMed Web of Science ®Google Scholar
• Jiang C, Lu Y, Zhang S, Huang Y. Systemic immune-inflammation index is superior to neutrophil to lymphocyte ratio in prognostic assessment of breast cancer patients undergoing neoadjuvant chemotherapy. Biomed Res Int. 2020;2020:7961568. doi:10.1155/2020/7961568
   PubMed Web of Science ®Google Scholar
• Kariri YA, Aleskandarany MA, Joseph C, et al. Molecular complexity of lymphovascular invasion: the role of cell migration in breast cancer as a prototype. Pathobiology. 2020;87(4):218–231. doi:10.1159/000508337
   PubMed Web of Science ®Google Scholar
• Chen DD, Ji JA, Yan HC, Huang GH, Fang XJ. Effect of CD44st and HER2 expression on the postoperative prognosis of breast cancer patients. Onco Targets Ther. 2019;12:577–585. doi:10.2147/OTT.S180972
   PubMed Web of Science ®Google Scholar
• Shi P, Chen C, Yao Y. Correlation between HER-2 gene amplification or protein expression and clinical pathological features of breast cancer. Cancer Biother Radiopharm. 2019;34(1):42–46. doi:10.1089/cbr.2018.2576
   PubMed Web of Science ®Google Scholar